» Articles » PMID: 382866

The Tumoricidal Properties of Inflammatory Tissue Macrophages and Multinucleate Giant Cells

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1979 Aug 1
PMID 382866
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Peritoneal exudate cells from C3H/HeN mice infected with bacille Calmette Guérin (BCG) and subcutaneous inflammatory macrophages from uninfected mice exhibit spontaneous cytotoxicity for tumor cells in vitro, but their tumoricidal activity can be increased by incubation in vitro with lymphokines released by mitogen- or antigen-stimulated lymphocytes. Inflammatory macrophages from these sites are only susceptible to activation in vitro by lymphokines for a short period (less than 4 days) following their initial emigration from the circulation to the site of inflammation. The expression of tumoricidal activity by activated macrophages is similarly short-lived (less than 4 days). Once the tumoricidal state is lost it cannot be restored by further incubation with lymphokines in vitro. Fusion of macrophages to form multinucleate giant cells (MGCs) accompanies the loss of tumoricidal activity and the onset of resistance to activation by lymphokines, but the fusion process is not responsible for these changes, since unfused macrophages are similarly affected. Activation and acquisition of tumoricidal properties is confined to young macrophages recruited from the circulation during acute inflammation. Older macrophages and MGCs in chronic inflammatory lesions in which recruitment of new macrophages has ceased are nontumoricidal and are refractory to activation by lymphokines in vitro. These findings are discussed in relation to the efficiency of macrophage-mediated destruction of tumors in vivo and the amplification of macrophage antitumor activity by immunotherapeutic agents.

Citing Articles

Generation of multinucleated giant cells in vitro by culture of human monocytes with Mycobacterium bovis BCG in combination with cytokine-containing supernatants.

Gasser A, Most J Infect Immun. 1998; 67(1):395-402.

PMID: 9864241 PMC: 96322. DOI: 10.1128/IAI.67.1.395-402.1999.


Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes.

Sone S, Bucana C, Hoyer L, Fidler I Am J Pathol. 1981; 103(2):234-46.

PMID: 7234965 PMC: 1903832.


Tuberculin hypersensitivity hepatitis in mice infected with Mycobacterium bovis (BCG).

FERLUGA J Am J Pathol. 1981; 105(1):82-90.

PMID: 7027805 PMC: 1903857.


Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.

Fidler I, Poste G Springer Semin Immunopathol. 1982; 5(2):161-74.

PMID: 6755782 DOI: 10.1007/BF00199794.


Macrophage polykaryon formation in vitro by peritoneal cells from mice given injections of sodium periodate.

Weinberg J Am J Pathol. 1983; 110(2):182-92.

PMID: 6297306 PMC: 1916152.


References
1.
KAPLOW L . SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE. Blood. 1965; 26:215-9. View

2.
Poste G, Kirsh R, Fogler W, Fidler I . Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res. 1979; 39(3):881-92. View

3.
NORTH R . The concept of the activated macrophage. J Immunol. 1978; 121(3):806-9. View

4.
Chapman Jr H, Hibbs Jr J . Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid. Science. 1977; 197(4300):282-5. DOI: 10.1126/science.195338. View

5.
Normann S, Sorkin E . Inhibition of macrophage chemotaxis by neoplastic and other rapidly proliferating cells in vitro. Cancer Res. 1977; 37(3):705-11. View